gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2022-32-6-53-59gastro-j-595Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYДиагностические возможности определения уровня фекального кальпротектина в клинической практикеDiagnostic Possibilities of Determining the Level of Faecal Calprotectin in Clinical Practicehttps://orcid.org/0000-0002-1395-9566ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского.

119435, Москва, ул. Погодинская ул., д. 1, стр. 1

Arkadiy A. Sheptulin — Dr. Sci. (Med.), Prof., Chair of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1, bld. 1

arkalshep@gmail.comhttps://orcid.org/0000-0002-5116-2144КардашеваС. С.KardashevaS. S.

Кардашева Светлана Станиславовна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифософского.

119435, Москва, ул. Погодинская ул., д. 1, стр. 1

Svetlana S. Kardasheva — Cand. Sci. (Med.), Associate Professor, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).

119991, Moscow, Pogodinskaya str., 1/1

svetlanakardasheva@gmail.comhttps://orcid.org/0000-0002-6154-8163КурбатоваА. А.KurbatovaA. A.

Курбатова Анастасия Александровна — кандидат медицинских наук, ассистент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского.

119435, Москва, ул. Погодинская ул., д. 1, стр. 1

Anastasya A. Kurbatova — Cand. Sci. (Med.), Assis-tant, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).

119991, Moscow, Pogodinskaya str., 1/1

maksnastia@mail.ruФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2022301220223265359Copyright © Шептулин А.А., Кардашева С.С., Курбатова А.А., 20232023Шептулин А.А., Кардашева С.С., Курбатова А.А.Sheptulin A.A., Kardasheva S.S., Kurbatova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/595Цель публикации

Цель публикации. Провести анализ публикаций, посвященных современным возможностям определения уровня фекального кальпротектина (ФКП) в диагностике различных заболеваний.

Основные положения

Основные положения. У больных с уже установленным диагнозом воспалительных заболеваний кишечника (ВЗК) динамический контроль уровня ФКП позволяет оценить течение и прогноз заболевания, а также эффективность лечения. Определение ФКП помогает при проведении первичной диагностики ВЗК (язвенного колита, болезни Крона, микроскопического колита), способствуя их разграничению с функциональными расстройствами кишечника, а также в оценке течения дивертикулярной болезни кишечника и целиакии. Обсуждается также вопрос о возможности использования ФКП как маркера колоректального рака (КРР) и аденоматозных полипов толстой кишки.

Заключение

Заключение. Определение уровня ФКП играет важную роль в диагностике и оценке течения ряда гастроэнтерологических заболеваний (прежде всего ВЗК). Значение ФКП как маркера КРР требует дальнейших исследований.

Aim

Aim: to analyze the publications devoted to the modern possibilities of determining the level of faecal calprotectin (FCP) in the diagnosis of various diseases.

Key points

Key points. In patients with already established diagnosis of inflammatory bowel diseases (IBD), dynamic monitoring of the level of FCP allows to assess the course and prognosis of the disease, as well as the effectiveness of treatment. The determining of FCP helps in the primary diagnosis of IBD (ulcerative colitis, Crohn's disease, microscopic colitis), contributing to their differentiation from functional bowel disorders, as well as in assessing the course of diverticular intestinal disease and celiac disease. The possibility of using FCP as a marker of colorectal cancer (CRC) and adenomatous polyps of the colon is also discussed.

Conclusion

Conclusion. Determining the level of FCP plays an important role in the diagnosis and assessment of the course of a number of gastroenterological diseases (primarily IBD). The significance of FCP as a marker of CRC requires further research.

фекальный кальпротектинвоспалительные заболевания кишечникафункциональные расстройства кишечникаколоректальный ракfaecal calprotectininflammatory bowel diseasesfunctional bowel disorderscolorectal cancerReferencesRokkas T., Portincasa P., Koutroubakis I.E. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018;27(3):299—306. DOI: 10.15403/jgld.2014.1121.273.ptiRokkas T., Portincasa P., Koutroubakis I.E. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018;27(3):299—306. DOI: 10.15403/jgld.2014.1121.273.ptiОсипенко М.Ф., Ливзан М.А., Скалинская М.И., Лялюкова Е.А. Концентрация фекального кальпротектина в дифференциальной диагностике заболеваний кишечника. Тер. Архив. 2015;87(2):30—3. DOI: 10.17116/terarkh201587230-33Osipenko M.F., Livzan M.A., Skalinskaya M.I., Lyalyukova E.A. The concentration of fecal calprotectin in the differential diagnosis of intestinal diseases. Ter Arkhiv. 2015;87(2):30—3 (In Russ.). DOI: 10.17116/terarkh201587230-33Никитин А.В., Васильева Л.В., Матюхин А.А. Неинвазивные маркеры активности воспалительных заболеваний кишечника. Рос журн гастроэнтерол гепатол колопроктол. 2016;26(6):106—11. DOI: 10.22416/1382-4376-2016-6-106-111Nikitin A.V., Vasilyeva L.V., Matiukhin A.A. Noninvasive markers of inflammatory bowel disease activity. Ross z gastroenterol gepatol koloproktol. 2016;26(6):106—11 (In Russ.). DOI: 10.22416/1382-4376-2016-6-106-111Hart L., Chavannes M., Kherad O., Maedler C., Mourad N., Marcus V., et al. Faecal calprotectin predicts endoscopic and histological activity in clinically quiescent ulcerative colitis. J Crohns Colitis. 2020;14(1):46-52. DOI: 10.1093/ecco-jcc/jjz107Hart L., Chavannes M., Kherad O., Maedler C., Mourad N., Marcus V., et al. Faecal calprotectin predicts endoscopic and histological activity in clinically quiescent ulcerative colitis. J Crohns Colitis. 2020;14(1):46-52. DOI: 10.1093/ecco-jcc/jjz107Nakov R., Nakov V., Gerova V., Tankova L. Fecal calprotectin correlates well with endoscopic activity in ulcerative colitis patients. J Gastrointestin Liver Dis. 2018;27(4):473-4. DOI: 10.15403/jgld.2014.1121.27Nakov R., Nakov V., Gerova V., Tankova L. Fecal calprotectin correlates well with endoscopic activity in ulcerative colitis patients. J Gastrointestin Liver Dis. 2018;27(4):473-4. DOI: 10.15403/jgld.2014.1121.27Lin W.C., Wong J.M., Tung C.C., Lin C.P., Chou J.W., Wang H.Y., et al. Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol. 2015;21(48):13566-73. DOI: 10.3748/wjg.v21.i48.13566Lin W.C., Wong J.M., Tung C.C., Lin C.P., Chou J.W., Wang H.Y., et al. Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol. 2015;21(48):13566-73. DOI: 10.3748/wjg.v21.i48.13566Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И., Абдулхаков Р.А., Алексеева О.П., Ачкасов С.И. и др. Рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению взрослых больных язвенным колитом. Рос журн гастроэнтерол гепатол колопроктол. 2015;25(1):48—65.Ivashkin V.T., Shelygin Yu.A., Abdulganieva D.I., Abdulkhakov R.A., Alexeyeva O.P., Achkasov S.I., et al. Guidelines of the Russian gastroenterological association and Russian association of coloproctology on diagnostics and treatment of ulcerative colitis in adults. Russian z gastroenterol gepatol koloproktol. 2015;25(1):48-65 (In Russ.).Conroy S., Hale M.F., Cross S.S., Swallow K., Sidhu R.H., Sargur R., Lobo A.J. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. J Clin Pathol. 2018;71(4):316-22. DOI: 10.1136/jclinpath-2017-204506Conroy S., Hale M.F., Cross S.S., Swallow K., Sidhu R.H., Sargur R., Lobo A.J. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. J Clin Pathol. 2018;71(4):316-22. DOI: 10.1136/jclinpath-2017-204506Kopylov U., Yung D.E., Engel T., Avni T., Battat R., Ben-Horin S., et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(10):1137-44. DOI: 10.1097/MEG.0000000000000692Kopylov U., Yung D.E., Engel T., Avni T., Battat R., Ben-Horin S., et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(10):1137-44. DOI: 10.1097/MEG.0000000000000692Sipponen T., Haapamaki J., Savilahti E., Alfthan H., Hamalainen E., Rautiainen H., et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47(7):778-84. DOI: 10.3109/00365521.2012.677953Sipponen T., Haapamaki J., Savilahti E., Alfthan H., Hamalainen E., Rautiainen H., et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47(7):778-84. DOI: 10.3109/00365521.2012.677953Costa F., Mumolo M.G., Ceccarelli L., Bellini M.R., Romano M.R., Sterpi C., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54(3):364-8. DOI: 10.1136/gut.2004.043406Costa F., Mumolo M.G., Ceccarelli L., Bellini M.R., Romano M.R., Sterpi C., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54(3):364-8. DOI: 10.1136/gut.2004.043406Molander P., Farkkila M., Ristimaki A., Salminen K., Kemppainen H., Blomster T., et al. Does fecal calprotectin predict short-term relapse after stopping TN-Fa-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015;9(1):33—40. DOI: 10.1016/j.crohns.2014.06.01Molander P., Farkkila M., Ristimaki A., Salminen K., Kemppainen H., Blomster T., et al. Does fecal calprotectin predict short-term relapse after stopping TN-Fa-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015;9(1):33—40. DOI: 10.1016/j.crohns.2014.06.01Bjorkesten C.G., Jussila A., Kemppainen H., Hallinen T., Soini E., Mankinen P., et al. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol. 2019;54(10):1226—32. DOI: 10.1080/00365521.2019.1667426Bjorkesten C.G., Jussila A., Kemppainen H., Hallinen T., Soini E., Mankinen P., et al. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol. 2019;54(10):1226—32. DOI: 10.1080/00365521.2019.1667426Lozoya Angulo M.E., de Las Heras Gomez I., Martinez Villanueva M., Noguera Velasco J.A., Aviles Plaza F. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders. Gastroenterol Hepatol. 2017;40(3): 125-31. DOI: 10.1016/j.gastrohep.2016.04.009Lozoya Angulo M.E., de Las Heras Gomez I., Martinez Villanueva M., Noguera Velasco J.A., Aviles Plaza F. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders. Gastroenterol Hepatol. 2017;40(3): 125-31. DOI: 10.1016/j.gastrohep.2016.04.009Banerjee A., Srinivas M., Eyre R., Ellis R., Waugh N., Bardhan K.D. Basumani P. Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice. Frontline Gastroenterol. 2015;6(1):20-6. DOI: 10.1136/flgastro-2013-100429Banerjee A., Srinivas M., Eyre R., Ellis R., Waugh N., Bardhan K.D. Basumani P. Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice. Frontline Gastroenterol. 2015;6(1):20-6. DOI: 10.1136/flgastro-2013-100429Waugh N., Cummins E., Royle P., Kandala N.B., Shyangdan D., Arasaradnam R., et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17(55):xv-xix, 1-211. DOI: 10.3310/hta17550Waugh N., Cummins E., Royle P., Kandala N.B., Shyangdan D., Arasaradnam R., et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17(55):xv-xix, 1-211. DOI: 10.3310/hta17550An Y.-K., Prince D., Gardiner F., Neeman T., Linedale E.C., Andrews J.M., et al. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis. Med J Aust. 2019;211(10):461-7. DOI: 10.5694/mja2.50384An Y.-K., Prince D., Gardiner F., Neeman T., Linedale E.C., Andrews J.M., et al. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis. Med J Aust. 2019;211(10):461-7. DOI: 10.5694/mja2.50384Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., Белоусова Е.А., Бениашвили А.Г. Е.А.Васильев С.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол. 2017;27(5):76-93. DOI: 10.22416/1382-4376-2017-27-5-76-93Ivashkin V.T., Shelygin Yu.A., Baranskaya Ye.K., Belousova Ye.A., Beniashvili A.G., Vasilyev S.V. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian z gastroenterol gepatol koloproktol. 2017;27(5):76-93 (In Russ.). DOI: 10.22416/1382-4376-2017-27-5-76-93Melchior C., Aziz M., Aubry T., Gourcerol G., Quillaume G., Quillard M., et al. Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study. United European Gastroenterol J. 2017 Mar;5(2):261-9. DOI: 10.1177/2050640616650062Melchior C., Aziz M., Aubry T., Gourcerol G., Quillaume G., Quillard M., et al. Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study. United European Gastroenterol J. 2017 Mar;5(2):261-9. DOI: 10.1177/2050640616650062Safwat E., Salah M., Hussein H. Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study. Arab J Gastroenterol. 2020;21(4):273-7. DOI: 10.1016/j.ajg.2020.08.003Safwat E., Salah M., Hussein H. Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study. Arab J Gastroenterol. 2020;21(4):273-7. DOI: 10.1016/j.ajg.2020.08.003Kan Y.M., Chu S.Y., Loo C.K. Diagnostic accuracy of fecal calprotectin in predicting significant gastrointestinal diseases. JGH Open. 2021;5(6):647-52. DOI: 10.1002/jgh3.12548Kan Y.M., Chu S.Y., Loo C.K. Diagnostic accuracy of fecal calprotectin in predicting significant gastrointestinal diseases. JGH Open. 2021;5(6):647-52. DOI: 10.1002/jgh3.12548Freeman K., Taylor-Phillips S., Willis B.H., Ryan R., Clarke A. Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data. BMJ Open. 2021;11(2):e044177. DOI: 10.1136/bmjop-en-2020-044177Freeman K., Taylor-Phillips S., Willis B.H., Ryan R., Clarke A. Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data. BMJ Open. 2021;11(2):e044177. DOI: 10.1136/bmjop-en-2020-0441770stgard R.D., Deleuran B.W., Dam M.Y., Hansen I.T., Jurik A.G., Glerup H. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scand J Rheumatol. 2018;47(1):48-55. DOI: 10.1080/03009742.2017.12992160stgard R.D., Deleuran B.W., Dam M.Y., Hansen I.T., Jurik A.G., Glerup H. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scand J Rheumatol. 2018;47(1):48-55. DOI: 10.1080/03009742.2017.1299216Fauny M., D'Amico F., Bonovas S., Netter P., Danese S., Loeuille D., Peyrin-Biroulet L.J. Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. Crohns Colitis. 2020;14(5):688-693. DOI: 10.1093/ecco-jcc/jjz205. PMID: 31858121Fauny M., D'Amico F., Bonovas S., Netter P., Danese S., Loeuille D., Peyrin-Biroulet L.J. Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. Crohns Colitis. 2020;14(5):688-693. DOI: 10.1093/ecco-jcc/jjz205. PMID: 31858121Von Arnim U, Wex T, Ganzert C, Schulz C, Malfertheiner P. Fecal calprotectin:a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016;9:97-103. DOI: 10.2147/CEG.S97701Von Arnim U, Wex T, Ganzert C, Schulz C, Malfertheiner P. Fecal calprotectin:a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016;9:97-103. DOI: 10.2147/CEG.S97701Wildt S., Nordgaard-Lassen I., Bendtsen F., Rumessen J.J. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19(7):567-74. DOI: 10.1097/MEG.0b013e328058ed76Wildt S., Nordgaard-Lassen I., Bendtsen F., Rumessen J.J. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19(7):567-74. DOI: 10.1097/MEG.0b013e328058ed76Tursi A., Brandimarte G., Elisei W., Giorgetti G.M., Inchingolo C.D., Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis. 2009;24(1):49-55. DOI: 10.1007/s00384-008-0595-9Tursi A., Brandimarte G., Elisei W., Giorgetti G.M., Inchingolo C.D., Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis. 2009;24(1):49-55. DOI: 10.1007/s00384-008-0595-9Ивашкин В.Т., Шелыгин Ю.А., Ачкасов С.И., Васильев С.В., Григорьев Е.Г., Дудка В.В. и др. Рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению взрослых больных дивертикулярной болезнью ободочной кишки. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(1): 65-80. DOI: 10.22416/1382-4376-2016-26-1-65-80Ivashkin V.T., Shelygin Yu.A., Achkasov S.I., Vasilyev S.V., Grigoryev Ye.G., Dudka V.V., et al. Diagnostics and treatment of diverticular disease of the colon: guidelines of the Russian gastroenterological Association and Russian Association of Coloproctology. Ross z gastroenterol gepatol koloproctol. 2016;26(1):65-80 (In Russ.). DOI: 10.22416/1382-4376-2016-26-1-65-80Montalto M., Santoro L., Curigliano V., D'Onofrio F., Cammarota G., Panunzi S., et al. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol. 2007;42(8):957-61. DOI: 10.1080/00365520601173632Montalto M., Santoro L., Curigliano V., D'Onofrio F., Cammarota G., Panunzi S., et al. Faecal calprotectin concen-trations in untreated coeliac patients. Scand J Gastroenterol. 2007;42(8):957-61. DOI: 10.1080/00365520601173632Ertekin V., Selimoglu M.A., Turgut A., Bakan N. Fecal calprotectin concentration in celiac disease. J Clin Gastroenterol. 2010;44(8):544-6. DOI: 10.1097/MCG.0b013e3181cadbc0Ertekin V., Selimoglu M.A., Turgut A., Bakan N. Fecal calprotectin concentration in celiac disease. J Clin Gastroenterol. 2010;44(8):544-6. DOI: 10.1097/MCG.0b013e3181cadbc0Balamtekin N., Baysoy G., Uslu N., Orhan D., Acoren Z., Ozen H., et al. Fecal calprotectin concentration is increased in children with celiac disease:relation with histopathological findings. Turk J Gastroenterol. 2012;23(5):503-8. DOI: 10.4318/tjg.2012.0366Balamtekin N., Baysoy G., Uslu N., Orhan D., Acoren Z., Ozen H., et al. Fecal calprotectin concentration is increased in children with celiac disease:relation with histopathological findings. Turk J Gastroenterol. 2012;23(5):503-8. DOI: 10.4318/tjg.2012.0366Tibble J., Sigthorsson G., Foster G. Sherwood R., Fagerhol M., Bjarnason J. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49(3):402-8. DOI: 10.1136/gut.49.3.402Tibble J., Sigthorsson G., Foster G. Sherwood R., Fagerhol M., Bjarnason J. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49(3):402-8. DOI: 10.1136/gut.49.3.402Ye X., Huai J., Ding J. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis. Turk J Gastroenterol. 2018;29(4):397-405. DOI: 10.5152/tjg.2018.17606Ye X., Huai J., Ding J. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis. Turk J Gastroenterol. 2018;29(4):397-405. DOI: 10.5152/tjg.2018.17606Turvill J., Aghahoseini A., Sivarajasingham N., Abbas K., Choudhry M., Polyzois K. et al. Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study. Br J Gen Pract. 2016;66(648):e499-506. DOI: 10.3399/bjgp16X685645Turvill J., Aghahoseini A., Sivarajasingham N., Abbas K., Choudhry M., Polyzois K. et al. Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study. Br J Gen Pract. 2016;66(648):e499-506. DOI: 10.3399/bjgp16X685645Lundgren D., Eklof V., Palmquist R., Hultdin J., Karling P. Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy. Scand J Gastroenterol. 2019;54(2):152-7. DOI: 10.1080/00365521.2019.1566493Lundgren D., Eklof V., Palmquist R., Hultdin J., Karling P. Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy. Scand J Gastroenterol. 2019;54(2):152-7. DOI: 10.1080/00365521.2019.1566493Hovstadius H, Lundgren D, Karling P. Elevated faecal calprotectin in patients with a normal colonoscopy: does it matter in clinical practice? A retrospective observational study. Inflamm Intest Dis. 2021 May;6 (2):101-8. DOI: 10.1159/000513473Hovstadius H, Lundgren D, Karling P. Elevated faecal calprotectin in patients with a normal colonoscopy: does it matter in clinical practice? A retrospective observational study. Inflamm Intest Dis. 2021 May;6 (2):101-8. DOI: 10.1159/000513473

The authors declare that there are no conflicts of interest present.